About Hookipa biotech ag
Hookipa Biotech AG: Revolutionizing the Fight Against Infectious Diseases and Cancer
Hookipa Pharma Inc. is a clinical stage biotechnology company that is dedicated to developing innovative products to prevent and cure infectious diseases and cancer. The company was founded in 2011 by a team of experienced scientists who shared a common vision of revolutionizing the field of immunotherapy.
With its headquarters in Vienna, Austria, Hookipa Biotech AG has established itself as a leader in the development of cutting-edge technologies that reprogram and stimulate the immune system. The company's proprietary platform technology, Vaxwave®, is designed to generate potent immune responses against infectious diseases and cancer.
Vaxwave® works by using viral vectors to deliver specific antigens directly into dendritic cells, which are specialized cells that play a critical role in initiating an immune response. By targeting dendritic cells with Vaxwave®, Hookipa Biotech AG can activate both CD4+ T-cells (helper T-cells) and CD8+ T-cells (killer T-cells), which work together to eliminate infected or cancerous cells.
One of Hookipa Biotech AG's most promising product candidates is HB-101, a prophylactic vaccine for cytomegalovirus (CMV) infection. CMV is one of the most common viral infections worldwide, affecting up to 80% of adults by age 40. While CMV infection usually causes no symptoms in healthy individuals, it can be life-threatening for people with weakened immune systems such as transplant recipients or HIV patients.
HB-101 has shown promising results in preclinical studies, demonstrating strong antibody responses against multiple strains of CMV without causing any adverse effects. In addition to HB-101, Hookipa Biotech AG has several other product candidates in various stages of development for infectious diseases such as Zika virus, Ebola virus, and Lassa fever.
In addition to its work on infectious diseases, Hookipa Biotech AG is also developing immunotherapies for cancer. The company's lead product candidate in this area is HB-201, a therapeutic vaccine for human papillomavirus (HPV)-associated cancers. HPV is a common sexually transmitted infection that can cause several types of cancer, including cervical, anal, and head and neck cancers.
HB-201 works by targeting the E6 and E7 oncoproteins produced by HPV-infected cells. By delivering these antigens directly to dendritic cells using Vaxwave®, HB-201 can activate an immune response against the cancerous cells while leaving healthy cells unharmed.
Hookipa Biotech AG has also developed a second-generation platform technology called TheraT® that uses RNA-based vectors to deliver therapeutic genes directly into target cells. TheraT® has shown promising results in preclinical studies for the treatment of genetic disorders such as hemophilia A and B.
In conclusion, Hookipa Biotech AG is a pioneering biotechnology company that is at the forefront of developing innovative products to prevent and cure infectious diseases and cancer. With its cutting-edge technologies such as Vaxwave® and TheraT®, Hookipa Biotech AG has positioned itself as a leader in the field of immunotherapy. As the company continues to advance its product candidates through clinical trials, it holds great promise for improving global health outcomes and revolutionizing medical treatments for infectious diseases and cancer.